BioCentury | Jan 6, 2020
Company News

Bancel letter showcases Moderna’s focus on mRNA vaccines

Moderna giving antiviral vaccines top billing in its sprawling mRNA pipeline reflects the growing consensus that the modality’s biggest near-term value lies in its potential to stoke immune responses. With 21 candidates spanning six treatment...
BioCentury | Aug 9, 2019
Finance

Stem cells (re)generate rewards for Versant, Bayer

The combination of stem cells, gene therapy and regenerative medicine was not in vogue in 2016, but Versant and Bayer felt it had enough promise to make a bet on creating and funding BlueRock. Now...
BioCentury | Aug 8, 2019
Company News

BlueRock becomes Bayer's cell therapy foundation

Three years after leading the $225 million series A round for stem cell company BlueRock, Bayer is doling out $240 million in cash up front to acquire the company outright. BlueRock Therapeutics L.P. will lay...
BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

Moderna Inc. (NASDAQ:MRNA) tumbled out of the gate on Dec. 7, losing $4.40 (19%) to $18.60 in its trading debut for a loss of $1.4 billion in market cap as U.S. stocks across the board...
BioCentury | Dec 8, 2018
Finance

Moderna’s land grab

A blockbuster IPO by Moderna Inc. (NASDAQ:MRNA) gives the company the opportunity to make the case for mRNA. With more money, and a broader and more advanced pipeline than other players in the mRNA space,...
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

Brushing aside market volatility that has led several biotechs to miss their desired valuations in recent weeks, Moderna Inc. (NASDAQ:MRNA) raised $604.3 million in an upsized IPO late Thursday through the sale of 26.3 million...
BioCentury | Nov 30, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
BioCentury | Nov 28, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
BioCentury | Oct 17, 2016
Politics, Policy & Law

Pruning REGROW

Senate Republican leaders think FDA is unnecessarily impeding the development of regenerative medicines, and they want to use the 21st Century Cures Act as a vehicle to reduce regulatory requirements to market cell- and tissue-based...
BioCentury | Jun 29, 2015
Financial News

Ankasa completes venture financing

Ankasa Regenerative Therapeutics Inc. , La Jolla, Calif. Business: Gene/Cell therapy, Musculoskeletal Date completed: 2015-06-23 Type: Venture financing Raised: $8.5 million Investors: Avalon Ventures; Heraeus; Correlation Ventures Note: Ankasa raised $8.5 million in a first tranche...
Items per page:
1 - 10 of 39
BioCentury | Jan 6, 2020
Company News

Bancel letter showcases Moderna’s focus on mRNA vaccines

Moderna giving antiviral vaccines top billing in its sprawling mRNA pipeline reflects the growing consensus that the modality’s biggest near-term value lies in its potential to stoke immune responses. With 21 candidates spanning six treatment...
BioCentury | Aug 9, 2019
Finance

Stem cells (re)generate rewards for Versant, Bayer

The combination of stem cells, gene therapy and regenerative medicine was not in vogue in 2016, but Versant and Bayer felt it had enough promise to make a bet on creating and funding BlueRock. Now...
BioCentury | Aug 8, 2019
Company News

BlueRock becomes Bayer's cell therapy foundation

Three years after leading the $225 million series A round for stem cell company BlueRock, Bayer is doling out $240 million in cash up front to acquire the company outright. BlueRock Therapeutics L.P. will lay...
BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

Moderna Inc. (NASDAQ:MRNA) tumbled out of the gate on Dec. 7, losing $4.40 (19%) to $18.60 in its trading debut for a loss of $1.4 billion in market cap as U.S. stocks across the board...
BioCentury | Dec 8, 2018
Finance

Moderna’s land grab

A blockbuster IPO by Moderna Inc. (NASDAQ:MRNA) gives the company the opportunity to make the case for mRNA. With more money, and a broader and more advanced pipeline than other players in the mRNA space,...
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

Brushing aside market volatility that has led several biotechs to miss their desired valuations in recent weeks, Moderna Inc. (NASDAQ:MRNA) raised $604.3 million in an upsized IPO late Thursday through the sale of 26.3 million...
BioCentury | Nov 30, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
BioCentury | Nov 28, 2018
Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
BioCentury | Oct 17, 2016
Politics, Policy & Law

Pruning REGROW

Senate Republican leaders think FDA is unnecessarily impeding the development of regenerative medicines, and they want to use the 21st Century Cures Act as a vehicle to reduce regulatory requirements to market cell- and tissue-based...
BioCentury | Jun 29, 2015
Financial News

Ankasa completes venture financing

Ankasa Regenerative Therapeutics Inc. , La Jolla, Calif. Business: Gene/Cell therapy, Musculoskeletal Date completed: 2015-06-23 Type: Venture financing Raised: $8.5 million Investors: Avalon Ventures; Heraeus; Correlation Ventures Note: Ankasa raised $8.5 million in a first tranche...
Items per page:
1 - 10 of 39